Glucocorticoids and intravenous immune globulins can stop platelets from degrading. Immunotherapy drugs, such as rituximab (Rituxan), can address autoimmune issues that may be contributing. Other options include thrombopoietin receptor agonists, such as eltrombopag (Promacta), which stimulate platelet production.